MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/jcp.0b013e318160738e

Медицинская библиотека · Journal of clinical psychopharmacology · 2008

Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder.

Raskin Joel, Wiltse Curtis G, Dinkel James J, Walker Daniel J, Desaiah Durisala, Katona Cornelius

СтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

OBJECTIVE

To compare the safety and tolerability profile of duloxetine versus placebo in elderly (> or = 65 years) patients with major depressive disorder (MDD).

METHODS

Patients were randomized (2:1) to duloxetine 60 mg/d (once daily) (n = 207) or placebo (n = 104) for 8 weeks. Safety and tolerability measures were analyzed in the total cohort of patients, as well as in subgroups defined by age and preexisting hypertension.

RESULTS

Patients had a median age of 72 years (65-90 years). No deaths occurred in the study. Discontinuation rates due to adverse events were similar for duloxetine and placebo (9.7% vs 8.7%). Treatment-emergent dry mouth, nausea, and diarrhea occurred significantly (P < or = 0.05) more frequently with duloxetine compared with placebo. Changes in supine and standing blood pressure (BP) and pulse and in corrected QT (QTc) interval were not significantly different between duloxetine and placebo, except for change in orthostatic systolic BP (-2.45 vs 0.93 mm Hg; P = .017). Incidences of sustained elevation in BP and treatment-emergent orthostatic hypotension were similar for duloxetine compared with placebo (0.5% vs 1.0% and 15.6% vs 20.5%, respectively). The duloxetine group showed significant weight loss compared with the placebo group (-0.73 kg vs -0.13 kg; P = 0.009). Of 5 hepatic analytes, the only significant difference was an increase in alkaline phosphatase in duloxetine compared with placebo (P = 0.017); this difference was not considered clinically relevant. The incidence of 1 or more discontinuation-emergent adverse events was not significantly different between the duloxetine and placebo groups (17.3% vs 11.3%).

CONCLUSIONS

This study suggests that duloxetine is safe and well tolerated in elderly patients with major depressive disorder.

Для цитирования: Raskin Joel, Wiltse Curtis G, Dinkel James J, Walker Daniel J, Desaiah Durisala, Katona Cornelius. Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder.. Journal of clinical psychopharmacology. 2008. DOI: 10.1097/jcp.0b013e318160738e.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.